More than half of physicians believe that religion and spirituality have a significant influence on patients’ health, according to a report in the April 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Asthma symptoms vary greatly among individuals and vary at times with each individual. In this comprehensive study in the April issue of Mayo Clinic Proceedings, researchers address the prevalence and process of step-down therapy as symptoms subside.
A detectable level of prostate-specific antigen (PSA) is the first indicator of recurrent prostate cancer after radical prostatectomy. In a new Mayo Clinic study, the concept of PSA doubling time (DT) is found to be a reliable tool to distinguish which patients have prolonged innocuous PSA levels after therapy from those who are at great risk for disease recurrence and death from prostate cancer.
Common practice in the treatment of adolescent eating disorder patients has been to exclude the parents. Many experts consider parents part of the problem and thus keep them away during therapy.
An RNA-binding protein that is overproduced in ovarian cancer may present a new target for diagnosis or treatment of ovarian and other cancers, according to researchers at the University of Illinois at Chicago.
Virologists in the Virginia-Maryland Regional College of Veterinary Medicine (VMRCVM) at Virginia Tech are looking at how a genetically modified variant of Avian Newcastle disease virus (NDV) can treat human prostate cancer.
A new study published in the Journal of the American Medical Association found no increased risk of heart attack for women in their 50s who were taking HRT.
The U.S. Patent and Trademark Office has upheld challenges by consumer advocates to three over-reaching patents on human embryonic stem cells and rejected patent claims by the Wisconsin Alumni Research Foundation (WARF), the Foundation for Taxpayer and Consumer Rights (FTCR) said.
A new drug called Eslicarbazepine (ESL) shows promise as a treatment for epilepsy patients whose symptoms remain uncontrolled with existing medications.
In advanced cancer, anti-tumor therapies often work only partially or not at all, and tumors progress following treatment.